In vitroandin vivoproperties differ among liquid intravenous immunoglobulin preparations

Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products

(2011) M. Etscheid et al.   VOX SANGUINIS

Safety of intravenous immunoglobulin treatment

(2010) James B Caress et al.   Expert Opinion On Drug Safety

Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology

(2009) H.-P. Hartung et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized Patients

(2009) J. Kahwaji et al.   Clinical Journal of the American Society of Nephrology

Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations

(2009) Guillaume Bussone et al.   PROTEOMICS

In vitrocomparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations

(2009) M. Spycher et al.   VOX SANGUINIS

Osmotic Nephrosis: Acute Kidney Injury With Accumulation of Proximal Tubular Lysosomes Due to Administration of Exogenous Solutes

(2008) Michael Dickenmann et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Investigations of prion and virus safety of a new liquid IVIG product

(2008) M. Stucki et al.   BIOLOGICALS

Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach

(2008) Amélie Servettaz et al.   PROTEOMICS

Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis

(2008) Zohra Daw et al.   TRANSFUSION